Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7951 to 8000 of 8141 results

  1. Zuranolone for treating severe postnatal depression ID6431

    Awaiting development [GID-TA11356] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Teprotumumab for treating thyroid eye disease ID 6432

    Awaiting development [GID-TA11531] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225]

    In development [GID-TA11263] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Artificial intelligence software to help detect fractures in the emergency department (provisional title)

    In development [GID-HTE10044] Expected publication date: 17 December 2024

    Health technology evaluations
    In development

  6. Linzagolix for treating pain caused by endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Single-step scaffold insertion for repairing symptomatic chondral knee defects

    Awaiting development [GID-IPG10364] Expected publication date: 17 September 2024

    Interventional procedures guidance
    Awaiting development

  8. Single-step scaffold insertion for repairing symptomatic chondral knee defects: interventional procedure consultation

    We are listening to your views on this Interventional procedures guidance. Comments close 22 May 2024.

    Interventional procedures guidance
    In consultation

  9. Elafibranor for treating primary biliary cholangitis [ID6331]

    In development [GID-TA11378] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Phrenic nerve pacing for ventilator-dependent high cervical spinal cord injury

    Awaiting development [GID-IPG10367] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  11. Phrenic nerve pacing for congenital central hypoventilation syndrome

    Awaiting development [GID-IPG10317] Expected publication date: 15 August 2024

    Interventional procedures guidance
    Awaiting development

  12. Caval valve implantation for tricuspid regurgitation

    Awaiting development [GID-IPG10344] Expected publication date: 21 August 2024

    Interventional procedures guidance
    Awaiting development

  13. Surgical Insertion of a Catheter based intravascular microaxial blood pump

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  14. One-piece closed bags for adults with a colostomy: Late Stage Assessment

    In development [GID-HTE10045] Expected publication date: TBC

    Health technology evaluations
    In development

  15. Rehabilitation for chronic neurological disorders including acquired brain injury

    In development [GID-NG10181] Expected publication date: 21 May 2025

    NICE guideline
    In development

  16. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    In development [GID-TA11394] Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast media

    In development [GID-NG10410] Expected publication date: 16 October 2024

    NICE guideline
    In development

  18. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

    In development [GID-HTE10035] Expected publication date: TBC

    Health technology evaluations
    In development

  19. Falls: assessment and prevention in older people and people 50 and over at higher risk (update)

    In development [GID-NG10228] Expected publication date: 26 March 2025

    NICE guideline
    In development

  20. Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]

    In development [GID-TA10907] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  22. Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 16 May 2024.

    Technology appraisal guidance
    In consultation

  23. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405: draft scope consultation

    We are listening to your views on this Health technology evaluation. Comments close 23 May 2024.

    Health technology evaluation
    In consultation

  24. Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]

    In development [GID-TA11131] Expected publication date: TBC

    Technology appraisal guidance
    In development

  25. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  26. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

    Technology appraisal guidance
    In development

  27. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  28. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

    Technology appraisal guidance
    Topic selection

  29. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

    Awaiting development [GID-TA11279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  30. Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]

    In development [GID-TA11062] Expected publication date: 30 October 2024

    Technology appraisal guidance
    In development

  31. Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]

    In development [GID-TA11045] Expected publication date: 20 November 2024

    Technology appraisal guidance
    In development

  32. Cabotegravir for preventing HIV-1 in adults and young people [ID6255]

    In development [GID-TA11304] Expected publication date: 13 November 2024

    Technology appraisal guidance
    In development

  33. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  34. Maternal and child nutrition

    In development [GID-NG10191] Expected publication date: 13 November 2024

    NICE guideline
    In development

  35. CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack

    In development [GID-DG10054] Expected publication date: 10 July 2024

    Diagnostics guidance
    In development

  36. Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]

    In development [GID-TA11471] Expected publication date: 03 July 2024

    Technology appraisal guidance
    In development

  37. Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants

    In development [GID-IPG10351] Expected publication date: 13 November 2024

    Interventional procedures guidance
    In development

  38. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

    Technology appraisal guidance
    In development

  40. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development [GID-TA11224] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  41. Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

    In development [GID-TA10948] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  42. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    In development [GID-TA10937] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Subcutaneous isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments TSID 11969

      Status ...

    Technology appraisal guidance
    Topic selection

  44. Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

    In development [GID-TA11512] Expected publication date: TBC

    Technology appraisal guidance
    In development

  45. RenalGuard Therapy for reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  46. Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID6302]

    In development [GID-TA11371] Expected publication date: 11 September 2024

    Technology appraisal guidance
    In development

  47. Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]

    In development [GID-TA11090] Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  49. Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction

    Awaiting development [GID-IPG10353] Expected publication date: 14 November 2024

    Interventional procedures guidance
    Awaiting development

  50. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]

    In development [GID-TA11450] Expected publication date: 16 October 2024

    Technology appraisal guidance
    In development